Toronto Dominion Bank Buys 3,131 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Toronto Dominion Bank lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 32.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,684 shares of the company’s stock after acquiring an additional 3,131 shares during the period. Toronto Dominion Bank’s holdings in Neurocrine Biosciences were worth $1,461,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NBIX. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the second quarter valued at approximately $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences in the 2nd quarter valued at $30,000. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences in the 2nd quarter worth $35,000. Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares during the last quarter. Finally, Plato Investment Management Ltd boosted its holdings in Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after acquiring an additional 130 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $126.70 on Monday. The stock’s fifty day moving average is $121.75 and its 200-day moving average is $130.62. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The stock has a market capitalization of $12.83 billion, a PE ratio of 33.97 and a beta of 0.34.

Insiders Place Their Bets

In other news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on NBIX. Raymond James reiterated an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Piper Sandler upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. HC Wainwright reiterated a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Finally, StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.18.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.